WO2006048427A1 - Verfahren zur herstellung chiraler 8-(3-amino-piperidin-1-yl)-xanthine - Google Patents
Verfahren zur herstellung chiraler 8-(3-amino-piperidin-1-yl)-xanthine Download PDFInfo
- Publication number
- WO2006048427A1 WO2006048427A1 PCT/EP2005/055711 EP2005055711W WO2006048427A1 WO 2006048427 A1 WO2006048427 A1 WO 2006048427A1 EP 2005055711 W EP2005055711 W EP 2005055711W WO 2006048427 A1 WO2006048427 A1 WO 2006048427A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- piperidine
- group
- phthalimido
- butyn
- Prior art date
Links
- 0 *C1CNCCC1 Chemical compound *C1CNCCC1 0.000 description 2
- HFZOBQSHTNNKFY-UHFFFAOYSA-N CC#CC[n]1c(Br)nc(N(C)C(N2)=O)c1C2=O Chemical compound CC#CC[n]1c(Br)nc(N(C)C(N2)=O)c1C2=O HFZOBQSHTNNKFY-UHFFFAOYSA-N 0.000 description 1
- RRUSJWINMRBVKJ-UHFFFAOYSA-N CC#CC[n]1c(Br)nc(N(C)C(N2Cc(nccc3)c3C#N)=O)c1C2=O Chemical compound CC#CC[n]1c(Br)nc(N(C)C(N2Cc(nccc3)c3C#N)=O)c1C2=O RRUSJWINMRBVKJ-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N N#Cc1cccnc1CCl Chemical compound N#Cc1cccnc1CCl FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N O=C(c1ccccc11)NC1=O Chemical compound O=C(c1ccccc11)NC1=O XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N O=C(c1ccccc11)OC1=O Chemical compound O=C(c1ccccc11)OC1=O LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the invention relates to an improved process for the preparation of chiral 8- (3-aminopiperidin-1-yl) xanthines, their enantiomers and their physiologically acceptable salts.
- R 2 in which R 1 is, for example, an optionally substituted arylmethyl or an optionally substituted heteroarylmethyl group, R 2 is, for example, an alkyl group and R 3 is, for example, an optionally substituted benzyl group or a straight-chain or branched alkenyl or alkynyl group, are already known from international applications WO 02/068420, WO 04/018468, WO 04/018467, WO2004 / 041820 and WO 2004/046148 are known in which compounds with valuable pharmacological properties are described, in particular an inhibitory effect on the activity of the enzyme dipeptidyl peptidase IV (DPP -IV).
- DPP -IV dipeptidyl peptidase IV
- compounds of this type are for the prevention or treatment of diseases or conditions associated with increased DPP-IV activity or which can be prevented or alleviated by reduction of DPP-IV activity, in particular diabetes mellitus type I or type II, Prediabetes, or decreased glucose tolerance.
- WO 04/018468 discloses a preparation process in which 8- (3-aminopiperidin-1-yl) xanthines are prepared by deprotection of a corresponding tert-butyl oxycarbonyl-protected derivative of the general formula (II) ,
- Suitable solvents are tetrahydrofuran (THF), dioxane, N, N-dimethylformamide (DMF), dimethylacetamide (DMA), N-methyl-2-pyrrolidone (NMP) or dimethyl sulfoxide (DMSO).
- THF tetrahydrofuran
- DMF N, N-dimethylformamide
- DMA dimethylacetamide
- NMP N-methyl-2-pyrrolidone
- DMSO dimethyl sulfoxide
- DMSO dimethyl sulfoxide
- phthalyl is deprotected by known methods. Possible cleavage methods are described, for example, by TW Greene in Protective Groups in Organic Synthesis, Wiley 1981 on page 265 (eg hydrazine in ethanol).
- X is a leaving group selected from the group of the halogens, for example a fluorine, chlorine or bromine atom, or the sulfonic acid esters, for example a phenylsulfonyloxy, p-toluenesulfonyloxy, methylsulfonyloxy or trifluoromethylsulfonyloxy group
- R 1 is a phenylcarbonylmethyl, benzyl, naphthylmethyl, pyridinylmethyl, pyrimidinylmethyl, quinolinylmethyl, isoquinolinylmethyl, quinazolinylmethyl, quinoxalinylmethyl, naphthyridinylmethyl or phenanthridinylmethyl group in which in each case the aromatic or heteroaromatic part is replaced by R 3 mono is - or disubstituted, where the substituents may be the same or different and
- R 3 represents a hydrogen, fluorine, chlorine or bromine atom or a cyano, methyl, trifluoromethyl, ethyl, phenyl, methoxy, difluoromethoxy, trifluoromethoxy or ethoxy group, or two radicals R a , if bound to adjacent carbon atoms, may also be a -O-CH 2 -O- or -O-CH 2 -CH 2 -O- group,
- R 2 is a methyl, ethyl, propyl, isopropyl, cyclopropyl or phenyl group and
- R 3 is a 2-buten-1-yl, 3-methyl-2-buten-1-yl, 2-butyn-1-yl, 2-fluorobenzyl, 2-chlorobenzyl, 2-bromobenzyl , 2-iodobenzyl, 2-methylbenzyl, 2- (trifluoromethyl) benzyl or 2-cyanobenzyl group.
- the process is for those compounds in which
- X is a chlorine or bromine atom
- R 1 is a phenylcarbonylmethyl, benzyl, naphthylmethyl, pyridinylmethyl, pyrimidinylmethyl, quinolinylmethyl, isoquinolinylmethyl, quinazolinylmethyl, quinoxalinylmethyl or naphthyridinylmethyl group in which the aromatic or heteroaromatic part in each case is mono- or disubstituted by R 3 is, wherein the substituents may be the same or different and
- R 3 is a hydrogen, fluorine or chlorine atom or a cyano, methyl, ethyl,
- R 2 is a methyl, ethyl, propyl, isopropyl, cyclopropyl or phenyl group and R 3 is a 2-buten-1-yl, 3-methyl-2-buten-1-yl, 2-butyn-1-yl, 2-fluorobenzyl, 2-chlorobenzyl, 2-bromobenzyl , 2-iodobenzyl, 2-methylbenzyl, 2- (trifluoromethyl) benzyl, or 2-cyanobenzyl group.
- X is a chlorine or bromine atom
- R 1 is a cyanobenzyl, (cyanopyridinyl) methyl, quinolinylmethyl, (methylquinolinyl) methyl, isoquinolinylmethyl, (methylisoquinolinyl) methyl, quinazolinylmethyl, (methylquinazolinyl) methyl, quinoxazinylmethyl, (methylquinoxalinyl) methyl, ( Dimethyoxinoxalinyl) methyl or naphthyridinylmethyl group,
- R 2 is a methyl, cyclopropyl or phenyl group
- R 3 represents a 2-butene-1-yl, 3-methyl-2-butene-1-yl, 2-butyn-1-yl, 2-chlorobenzyl, 2-bromobenzyl or 2-cyanobenzyl group .
- each (R) -3- (phthalimido) piperidine is used as the reagent.
- the preparation of the compounds of the formula (III) is described in the literature already cited above and is carried out by processes known per se.
- Another subject of the invention is a process for the preparation of optically active 3- (phthalimido) piperidine.
- 3-aminopyridine is first hydrogenated by means of processes known per se.
- the resulting racemic 3-aminopiperidine is then converted to the corresponding phthalimide using phthalic anhydride.
- the (R) -enantiomer can be selectively precipitated by means of D-tartaric acid.
- the (S) -enantiomer of (IV) can furthermore be obtained in a simple manner by addition of L-tartaric acid, without prior separation of the excess of D-tartaric acid still present in the mother liquor.
- the reaction also succeeds under less drastic pressures.
- the feed vessel is rinsed with 2 liters of 1, 4-dioxane. Thereafter, the reactor contents are heated to 6 0 C and stirred for about 2 hours.
- a mixture of 122 liters of water and 62.04 kg (775.31 mol) of sodium hydroxide solution (50%) is introduced and cooled to 6 ° C.
- the reaction mixture from the first reactor is added in portions.
- the internal temperature is a maximum of 11 ° C.
- the first reactor is first rinsed with 6 liters of 1, 4-dioxane and then with 6 liters of water. The resulting suspension is stirred for another 30 minutes at 5 ° C.
- the feed vessel is 2.5 Liters of N-methyl-2-pyrrolidone rinsed and then the reaction mixture for 2 hours at 140 0 C stirred. After completion of the reaction, the reaction mixture is cooled to 60 0 C and diluted with 80 liters of methanol. The resulting suspension is stirred for 30 minutes at 5O 0 C, then cooled to 23 ° C and stirred for 30 minutes. The product is then centrifuged off and washed 3 times with 20 liters of methanol each time. It is dried in a drying oven under inerting at 45 ° C ge.
- the combined toluene phases are washed twice with 8 liters of 75-80 0 C warm water. From the toluene phase 22 liters of toluene are distilled off under vacuum. To the resulting suspension 4 liters of tert-butyl methyl ether is added and then cooled to 0-5 0 C at 40-50 0 C. The product is isolated by filtration, washed with tert-butyl methyl ether and sucked dry. The wet crude substance is then heated to reflux with 5 times the amount of absolute ethanol and the hot solution is filtered through activated charcoal clear.
- step d Alternative method for step d:
- the organic phase is washed with 2.8 l of water at 55-65 0 C and then closing separated. 4.2 l of the organic phase are distilled off under reduced pressure. Then, at 65-75 ° C., 1, 4 l of methylcyclohexane are added, whereby the product crystallizes. The suspension is stirred for 8-16 h at 15-25 ° C and then cooled to 0-5 ° C. The product is isolated by filtration, washed with 4.2 l of methylcyclohexane and sucked dry and dried in vacuo at 35 ° C.
- the dried crude substance (991 g) is then heated to reflux with 5 times the amount of methanol, activated charcoal added and filtered.
- the filtrate is reduced by distilling off methanol to a volume of 1.5 l.
- the suspension is cooled to 0-5 0 C, stirred for 2 hours, filtered off with suction, washed with tert-butyl methyl ether and dried in a vacuum oven at 35 ° C.
- Variant to process step a 3-Covano-2- (chloromethyl) -pyridine 20.0 g (131.45 mmol) of 2-hydroxymethyl-3-pyridinecarboxamide are suspended in 110 ml of acetonitrile and heated to 78.degree. Within 15 minutes, 60.65 g (395.52 mmol) of phosphorus oxychloride are metered in and heated to 81 ° C. for 2 hours. After cooling to 22 ° C, the reaction mixture is stirred into 200 ml of 40 0 C warm water. After addition of 100 ml of toluene is neutralized with sodium hydroxide while cooling. After phase separation, the organic phase is washed with 100 ml of water. Separation of the organic phase and evaporation of the solvent in vacuo initially gives an oily residue which crystallizes on standing. Yield: 16.66 g (83% of theory)
- reaction mixture is cooled to 75 ° C Test ⁇ and diluted with 720 ml of methanol. Thereafter, 2.7 liters of water are added at 68-60 ° C and cooled to 25 ° C. The product is filtered off and washed with 2 liters of water. It is dried in an oven under inerting at 70 0 C.
- the crude product thus obtained is then stirred in 1 liter of methanol in the boiling heat, filtered hot with 200 ml of methanol and then dried at 70 0 C under inertization.
- the combined toluene phases are washed twice with 2 liters of 75-80 0 C warm water.
- the toluene phases are dried with sodium sulfate, filtered and then reduced by distillation in vacuo to a volume of about 430 ml.
- 1 liter of tert-butyl methyl ether zu ⁇ is then metered and then cooled to 0-5 0 C at 50-55 ° C.
- the product is isolated by filtration, washed with tert-butyl methyl ether and dried in a drying oven at 60 0 C.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005300559A AU2005300559B2 (en) | 2004-11-05 | 2005-11-02 | Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines |
MX2007005404A MX2007005404A (es) | 2004-11-05 | 2005-11-02 | Procedimiento para preparar 8-(3-amino-piperidin-1-il)-xantinas quirales. |
CN201710405988.3A CN107266449B (zh) | 2004-11-05 | 2005-11-02 | 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法 |
PL15200579T PL3029040T3 (pl) | 2004-11-05 | 2005-11-02 | Sposób wytwarzania chiralnej 8-(3-AMINOPIPERYDYN-1-YLO)-KSANTYNY |
CN200580037243.1A CN101048409B (zh) | 2004-11-05 | 2005-11-02 | 手性8-(3-氨基-哌啶-1-基)-黄嘌呤的制备方法 |
BRPI0517093A BRPI0517093B8 (pt) | 2004-11-05 | 2005-11-02 | processo para a produção de 8-(3-amino-piperidin-1-il)-xantinas quirais |
EA200700974A EA012163B1 (ru) | 2004-11-05 | 2005-11-02 | Способ получения хиральных 8-(3-аминопиперидин-1-ил)ксантинов |
EP05804601A EP1812438A1 (de) | 2004-11-05 | 2005-11-02 | Verfahren zur herstellung chiraler 8-(3-amino-piperidin-1-yl)-xanthine |
CA2586938A CA2586938C (en) | 2004-11-05 | 2005-11-02 | Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines |
KR1020127034452A KR101440796B1 (ko) | 2004-11-05 | 2005-11-02 | 키랄성 8-(3-아미노-피페리딘-1-일)크산틴의 제조 방법 |
NZ555324A NZ555324A (en) | 2004-11-05 | 2005-11-02 | Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines |
JP2007539576A JP5063356B2 (ja) | 2004-11-05 | 2005-11-02 | キラル8−(3−アミノ−ピペリジン−1−イル)−キサンチンの製造方法 |
KR1020077012615A KR101383610B1 (ko) | 2004-11-05 | 2005-11-02 | 키랄성 8-(3-아미노-피페리딘-1-일)크산틴의 제조 방법 |
EP19166570.2A EP3539956A1 (de) | 2004-11-05 | 2005-11-02 | Verfahren zur herstellung chiraler 8-(3-amino-piperidin-1-yl)-xanthine |
KR1020147013135A KR101583264B1 (ko) | 2004-11-05 | 2005-11-02 | 키랄성 8-(3-아미노-피페리딘-1-일)크산틴의 제조 방법 |
EP15200579.9A EP3029040B1 (de) | 2004-11-05 | 2005-11-02 | Verfahren zur herstellung chiraler 8-(3-amino-piperidin-1-yl)-xanthine |
MX2011008031A MX344285B (es) | 2004-11-05 | 2005-11-02 | Procedimiento para preparar 8-(3-amino-piperidin-1-il)-xantinas quirales. |
NO20071522A NO20071522L (no) | 2004-11-05 | 2007-03-23 | Fremgangsmate for fremstilling av kirale 8-(3-amino-piperidin-1-yl)-xantiner |
IL182923A IL182923A (en) | 2004-11-05 | 2007-05-02 | Method for Manufacturing 8 - (3-Amino-Piperidine-1-ram) - Chiral xanthines |
HK08103534.9A HK1109405A1 (en) | 2004-11-05 | 2008-03-31 | Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines 8-(3---1-)- |
IL211015A IL211015A0 (en) | 2004-11-05 | 2011-02-02 | Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004054054.3 | 2004-11-05 | ||
DE102004054054A DE102004054054A1 (de) | 2004-11-05 | 2004-11-05 | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006048427A1 true WO2006048427A1 (de) | 2006-05-11 |
WO2006048427A8 WO2006048427A8 (de) | 2007-08-02 |
Family
ID=36010287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/055711 WO2006048427A1 (de) | 2004-11-05 | 2005-11-02 | Verfahren zur herstellung chiraler 8-(3-amino-piperidin-1-yl)-xanthine |
Country Status (35)
Country | Link |
---|---|
US (6) | US7820815B2 (de) |
EP (4) | EP2287164B9 (de) |
JP (3) | JP5063356B2 (de) |
KR (3) | KR101583264B1 (de) |
CN (6) | CN102127080B (de) |
AR (1) | AR051947A1 (de) |
AU (1) | AU2005300559B2 (de) |
BR (1) | BRPI0517093B8 (de) |
CA (1) | CA2586938C (de) |
CY (1) | CY1115036T1 (de) |
DE (1) | DE102004054054A1 (de) |
DK (2) | DK3029040T3 (de) |
EA (3) | EA012163B1 (de) |
ES (2) | ES2458106T3 (de) |
HK (1) | HK1109405A1 (de) |
HR (1) | HRP20140373T2 (de) |
HU (1) | HUE044308T2 (de) |
IL (2) | IL182923A (de) |
ME (1) | ME01667B (de) |
MX (2) | MX344285B (de) |
MY (1) | MY145604A (de) |
NO (1) | NO20071522L (de) |
NZ (3) | NZ555324A (de) |
PE (2) | PE20100232A1 (de) |
PL (2) | PL2287164T3 (de) |
PT (1) | PT2287164E (de) |
RS (1) | RS53166B (de) |
SG (3) | SG189768A1 (de) |
SI (1) | SI2287164T1 (de) |
TR (1) | TR201908974T4 (de) |
TW (2) | TWI374885B (de) |
UA (1) | UA100221C2 (de) |
UY (1) | UY29190A1 (de) |
WO (1) | WO2006048427A1 (de) |
ZA (1) | ZA200701996B (de) |
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007014886A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Hydrochloride und hydrate von 1-[(3-cyano-pyridin-2-yl) methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-amino-piperidin-1-yl)-xanthin, deren herstellung und deren verwendung als arzneimittel |
EP2016079A1 (de) | 2006-05-04 | 2009-01-21 | Boehringer Ingelheim International GmbH | Polymorphe |
WO2009022007A1 (en) | 2007-08-16 | 2009-02-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative |
US7645763B2 (en) | 2004-02-23 | 2010-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition |
US7667035B2 (en) | 2004-05-10 | 2010-02-23 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
US7696212B2 (en) | 2002-11-08 | 2010-04-13 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
WO2010072776A1 (en) | 2008-12-23 | 2010-07-01 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
WO2010079197A1 (en) | 2009-01-07 | 2010-07-15 | Boehringer Ingelheim International Gmbh | Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor |
WO2010086411A1 (en) | 2009-01-29 | 2010-08-05 | Boehringer Ingelheim International Gmbh | Dpp-iv inhibitors for treatment of diabetes in paediatric patients |
WO2010092124A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof |
WO2010092125A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
WO2010092163A2 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Antidiabetic medications |
US7820815B2 (en) | 2004-11-05 | 2010-10-26 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines |
US7838529B2 (en) | 2002-08-22 | 2010-11-23 | Boehringer Ingelheim International Gmbh | Xanthine derivates, their preparation and their use in pharmaceutical compositions |
US7906539B2 (en) | 2004-06-24 | 2011-03-15 | Boehringer Ingelheim International Gmbh | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
WO2011039367A2 (en) | 2009-10-02 | 2011-04-07 | Boehringer Ingelheim International Gmbh | Therapeutic uses of pharmaceutical compositions |
WO2011064352A1 (en) | 2009-11-27 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
US8034941B2 (en) | 2003-06-18 | 2011-10-11 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
WO2011138380A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations comprising pioglitazone and linagliptin |
US8071583B2 (en) | 2006-08-08 | 2011-12-06 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus |
WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
US8119648B2 (en) | 2002-08-21 | 2012-02-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
WO2012065993A1 (en) | 2010-11-15 | 2012-05-24 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US8232281B2 (en) | 2006-05-04 | 2012-07-31 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
WO2012120040A1 (en) | 2011-03-07 | 2012-09-13 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor |
WO2013010964A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
WO2013074817A1 (en) | 2011-11-16 | 2013-05-23 | Assia Chemical Industries Ltd. | Solid state forms of linagliptin |
WO2013098372A1 (en) | 2011-12-29 | 2013-07-04 | Boehringer Ingelheim International Gmbh | Subcutaneous therapeutic use of dpp-4 inhibitor |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
WO2013131967A1 (en) | 2012-03-07 | 2013-09-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising metformin and a dpp -4 inhibitor or a sglt-2 inhibitor |
WO2013171756A1 (en) * | 2012-03-12 | 2013-11-21 | Cadila Healthcare Limited | Amorphous form of linagliptin and process for preparation thereof |
WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174769A1 (en) | 2012-05-25 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor |
WO2013174768A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US8697868B2 (en) | 2004-02-18 | 2014-04-15 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
WO2014059938A1 (zh) * | 2012-10-19 | 2014-04-24 | 药源药物化学(上海)有限公司 | 一种利拉列汀重要中间体的制备方法 |
WO2014097314A1 (en) * | 2012-12-17 | 2014-06-26 | Mylan Laboratories Ltd | An improved process for the preparation of linagliptin |
US8853156B2 (en) | 2008-08-06 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
WO2015004599A1 (en) * | 2013-07-11 | 2015-01-15 | Wockhardt Limited | An improved process for preparing linagliptin and its key intermediates |
US9155705B2 (en) | 2008-04-03 | 2015-10-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
EP2885302A4 (de) * | 2012-08-17 | 2016-03-09 | Glenmark Pharmaceuticals Ltd | Verfahren zur herstellung von dipeptidylpeptidasehemmern |
US9486526B2 (en) | 2008-08-06 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
WO2016207364A1 (en) | 2015-06-25 | 2016-12-29 | Boehringer Ingelheim International Gmbh | Process for the preparation of a xanthine-based compound |
EP3156048A1 (de) | 2015-10-13 | 2017-04-19 | Galenicum Health S.L. | Stabile pharmazeutische zubereitung von linagliptin in form von tabletten mit sofortiger freisetzung |
US9949998B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9949997B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
WO2020031040A1 (en) | 2018-08-06 | 2020-02-13 | Richter Gedeon Nyrt. | Process and intermediates for the preparation of boc-linagliptin |
EP3626238A1 (de) | 2008-08-15 | 2020-03-25 | Boehringer Ingelheim International GmbH | Dpp-4-inhibitoren zur verwendung bei der behandlung von wundheilung bei diabetischen patienten |
US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
WO2021160608A1 (en) | 2020-02-13 | 2021-08-19 | Zakłady Farmaceutyczne POLPHARMA S.A. | Pharmaceutical composition comprising linagliptin and metformin |
US11666590B2 (en) | 2013-04-18 | 2023-06-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2023156675A1 (en) | 2022-02-21 | 2023-08-24 | Krka, D.D., Novo Mesto | Process for purification of linagliptin |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
EP4364796A2 (de) | 2013-03-15 | 2024-05-08 | Boehringer Ingelheim International GmbH | Verwendung von linagliptin in der kardio- und renoprotektiven antidiabetischen therapie |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002234640B8 (en) * | 2001-02-24 | 2009-11-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivative, production and use thereof as a medicament |
US7569574B2 (en) | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
DE10254304A1 (de) * | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE10355304A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
US7393847B2 (en) * | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US7179809B2 (en) * | 2004-04-10 | 2007-02-20 | Boehringer Ingelheim International Gmbh | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions |
DE102004043944A1 (de) * | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
DE102004044221A1 (de) * | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
JP2011057619A (ja) * | 2009-09-10 | 2011-03-24 | Tokai Univ | 光学活性アミン化合物の製造方法、並びに、ジアステレオマー塩及びその製造方法 |
IT1403282B1 (it) | 2010-12-23 | 2013-10-17 | Dipharma Francis Srl | Procedimento per la preparazione di linagliptin |
EA023330B1 (ru) * | 2011-05-10 | 2016-05-31 | Сандоз Аг | Полиморфная форма бензоата линаглиптина |
CN102372691A (zh) * | 2011-11-15 | 2012-03-14 | 海门慧聚药业有限公司 | (r)-3-苯二甲酰亚胺哌啶酒石酸盐的制备工艺 |
CN102516225A (zh) * | 2011-11-18 | 2012-06-27 | 海门慧聚药业有限公司 | 新型医药中间体(r)-3-苯二甲酰亚胺哌啶盐酸盐的合成 |
US9056112B2 (en) | 2011-12-28 | 2015-06-16 | Dr. Reddy's Laboratories Limited | Process for preparation of pure linagliptin |
CN103450201B (zh) * | 2012-05-30 | 2017-04-12 | 博瑞生物医药(苏州)股份有限公司 | 手性8‑(3‑氨基哌啶‑1‑基)‑黄嘌呤的制备方法 |
WO2015011609A1 (en) | 2013-07-23 | 2015-01-29 | Ranbaxy Laboratories Limited | Process for the preparation of linagliptin and an intermediate thereof |
ITMI20131836A1 (it) * | 2013-11-06 | 2015-05-07 | Chemelectiva S R L | Processo ed intermedi per la preparazione di linagliptina |
WO2015087240A1 (en) | 2013-12-11 | 2015-06-18 | Ranbaxy Laboratories Limited | Process for the preparation of linagliptin and an intermediate thereof |
WO2015107533A1 (en) * | 2014-01-15 | 2015-07-23 | Harman Finochem Limited | A process for preparation of 1h-purine-2,6-dione, 8-[(3r)-3-amino-1-piperidinyl]-7 (2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2quinazolinyl) methyl] and its pharmaceutically acceptable salts |
CA2942631A1 (en) | 2014-03-14 | 2015-09-17 | Takeda Pharmaceutical Company Limited | Process for producing heterocyclic compound |
CN104478880B (zh) * | 2014-12-26 | 2016-03-02 | 浙江永太科技股份有限公司 | 作为dpp-iv抑制剂的双胍衍生物 |
CN104496989A (zh) * | 2014-12-26 | 2015-04-08 | 寿光富康制药有限公司 | 一种利格列汀工业化制备工艺 |
CN105367572B (zh) * | 2014-12-26 | 2017-03-29 | 浙江永太科技股份有限公司 | 一种制备作为二肽基肽酶‑4抑制剂的化合物的中间体 |
CN105503873B (zh) * | 2014-12-26 | 2017-03-22 | 浙江永太科技股份有限公司 | 一种作为二肽基肽酶‑4抑制剂的化合物的制备方法 |
CN104478879B (zh) * | 2014-12-26 | 2016-03-02 | 浙江永太科技股份有限公司 | 一种作为二肽基肽酶-4抑制剂的化合物 |
CN104557935B (zh) * | 2015-01-27 | 2016-08-17 | 江苏嘉逸医药有限公司 | 制备(r)-8-(3-氨基哌啶-1-基)-黄嘌呤的提纯方法 |
CN104844602B (zh) * | 2015-04-14 | 2018-07-20 | 威海迪素制药有限公司 | 一种利格列汀的制备方法 |
CN104892609B (zh) * | 2015-04-23 | 2017-06-20 | 深圳市海滨制药有限公司 | 一种利拉利汀中间体及其制备方法和应用 |
TWI682931B (zh) * | 2015-05-29 | 2020-01-21 | 大陸商江蘇天士力帝益藥業有限公司 | 黃嘌呤衍生物、其藥物組成物、其製劑以及其用途 |
US20180247672A1 (en) * | 2017-02-24 | 2018-08-30 | Entry Point Vr, Inc. | Bundling Separate Video Files to Support a Controllable End-User Viewing Experience with Frame-Level Synchronization |
IT201800005383A1 (it) | 2018-05-15 | 2019-11-15 | Intermedi e processi per la preparazione di linagliptin e suoi sali | |
CN110590780B (zh) * | 2019-10-29 | 2020-10-09 | 深圳市第二人民医院 | 治疗糖尿病的药物利拉利汀的制备方法 |
CN111187223B (zh) * | 2020-03-09 | 2022-02-22 | 沧州那瑞化学科技有限公司 | 利拉利汀中间体2-氯甲基-4-甲基喹唑啉的合成方法 |
CN112592320A (zh) * | 2020-12-22 | 2021-04-02 | 江苏慧聚药业有限公司 | 一种利拉利汀中间体的有关物质及其合成方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4005208A (en) * | 1975-05-16 | 1977-01-25 | Smithkline Corporation | N-Heterocyclic-9-xanthenylamines |
WO2002068420A1 (de) * | 2001-02-24 | 2002-09-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthinderivate, deren herstellung und deren verwendung als arzneimittel |
WO2004018468A2 (de) * | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als arzneimittel |
WO2004041820A1 (de) * | 2002-11-08 | 2004-05-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel |
WO2005085246A1 (de) * | 2004-02-18 | 2005-09-15 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer |
JP2006045156A (ja) * | 2004-08-06 | 2006-02-16 | Sumitomo Pharmaceut Co Ltd | 縮合ピラゾール誘導体 |
Family Cites Families (414)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2056046A (en) * | 1933-05-19 | 1936-09-29 | Rhone Poulenc Sa | Manufacture of bases derived from benz-dioxane |
US2375138A (en) * | 1942-05-01 | 1945-05-01 | American Cyanamid Co | Alkamine esters of aryloxymethyl benzoic acid |
US2629736A (en) * | 1951-02-24 | 1953-02-24 | Searle & Co | Basically substituted n-alkyl derivatives of alpha, beta, beta-triarylpropionamides |
US2730544A (en) * | 1952-07-23 | 1956-01-10 | Sahyun Lab | Alkylaminoalkyl esters of hydroxycyclohexylbenzoic acid |
US2750387A (en) * | 1953-11-25 | 1956-06-12 | Searle & Co | Basically substituted derivatives of diarylaminobenzamides |
DE1211359B (de) * | 1955-11-29 | 1966-02-24 | Oreal | Oxydationsmittelfreies Kaltfaerbemittel fuer menschliches Haar |
US2928833A (en) * | 1959-03-03 | 1960-03-15 | S E Massengill Company | Theophylline derivatives |
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
US3454635A (en) * | 1965-07-27 | 1969-07-08 | Hoechst Ag | Benzenesulfonyl-ureas and process for their manufacture |
US3673241A (en) * | 1968-04-04 | 1972-06-27 | Ciba Geigy Corp | Substituted benzaldehyde guanylhydrazones |
ES385302A1 (es) | 1970-10-22 | 1973-04-16 | Miquel S A Lab | Procedimiento para la obtencion de derivados trisubstitui- dos de etilendiamina. |
DE2205815A1 (de) | 1972-02-08 | 1973-08-16 | Hoechst Ag | Piperazinderivate und verfahren zu ihrer herstellung |
JPS5512435B2 (de) * | 1972-07-01 | 1980-04-02 | ||
US4061753A (en) | 1976-02-06 | 1977-12-06 | Interx Research Corporation | Treating psoriasis with transient pro-drug forms of xanthine derivatives |
DE2758025A1 (de) | 1977-12-24 | 1979-07-12 | Bayer Ag | Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung |
NO154918C (no) | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
DE2929596A1 (de) | 1979-07-21 | 1981-02-05 | Hoechst Ag | Verfahren zur herstellung von oxoalkyl-xanthinen |
CY1306A (en) | 1980-10-01 | 1985-12-06 | Glaxo Group Ltd | Aminoalkyl furan derivative |
US4382091A (en) | 1981-04-30 | 1983-05-03 | Syntex (U.S.A.) Inc. | Stabilization of 1-substituted imidazole derivatives in talc |
EP0109281A1 (de) | 1982-11-15 | 1984-05-23 | The Upjohn Company | Zusammensetzungen mit Gehalt an Flurbiprofen oder Ibuprofen |
JPS6092912A (ja) | 1983-10-27 | 1985-05-24 | Nippon Denso Co Ltd | 車高制御装置 |
FR2558162B1 (fr) * | 1984-01-17 | 1986-04-25 | Adir | Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant |
FI79107C (fi) * | 1984-06-25 | 1989-11-10 | Orion Yhtymae Oy | Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid. |
AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
US5258380A (en) * | 1985-06-24 | 1993-11-02 | Janssen Pharmaceutica N.V. | (4-piperidinylmethyl and -hetero)purines |
GB8515934D0 (en) * | 1985-06-24 | 1985-07-24 | Janssen Pharmaceutica Nv | (4-piperidinomethyl and-hetero)purines |
ES2058061T3 (es) | 1985-10-25 | 1994-11-01 | Beecham Group Plc | Derivado de piperidina, su preparacion y su uso como medicamento. |
US5433959A (en) | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
DE3683760D1 (de) | 1986-03-21 | 1992-03-12 | Heumann Pharma Gmbh & Co | Kristalline, wasserfreie sigma -form von 2-(4-(2-furoyl-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung. |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
EP0587255A1 (de) | 1986-05-05 | 1994-03-16 | The General Hospital Corporation | Insulinotropische Hormone |
AU619444B2 (en) | 1986-06-02 | 1992-01-30 | Nippon Chemiphar Co. Ltd. | 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives |
US4968672A (en) | 1987-01-02 | 1990-11-06 | The United States Of America As Represented By The Department Of Health And Human Services | Adenosine receptor prodrugs |
US4743450A (en) | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
JPS6440433A (en) | 1987-08-05 | 1989-02-10 | Green Cross Corp | Aqueous liquid composition of thrombin |
DE68920773T2 (de) | 1988-05-19 | 1995-05-18 | Chugai Pharmaceutical Co Ltd | Chinoloncarbonsäure-Derivate. |
US5329025A (en) * | 1988-09-21 | 1994-07-12 | G. D. Searle & Co. | 3-azido compound |
DE3926119A1 (de) | 1989-08-08 | 1991-02-14 | Bayer Ag | 3-amino-5-aminocarbonyl-1,2,4-triazol-derivate |
US5234897A (en) * | 1989-03-15 | 1993-08-10 | Bayer Aktiengesellschaft | Herbicidal 3-amino-5-aminocarbonyl-1,2,4-triazoles |
GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
DE3916430A1 (de) * | 1989-05-20 | 1990-11-22 | Bayer Ag | Verfahren zur herstellung von 3-amino-5-aminocarbonyl-1,2,4-triazol-derivaten |
IL94390A (en) | 1989-05-30 | 1996-03-31 | Merck & Co Inc | The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them |
US5332744A (en) * | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
US5223499A (en) * | 1989-05-30 | 1993-06-29 | Merck & Co., Inc. | 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
HU208115B (en) | 1989-10-03 | 1993-08-30 | Biochemie Gmbh | New process for producting pleuromutilin derivatives |
FR2654935B1 (fr) * | 1989-11-28 | 1994-07-01 | Lvmh Rech | Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux. |
EP0443983B1 (de) | 1990-02-19 | 1996-02-28 | Ciba-Geigy Ag | Acylverbindungen |
KR930000861B1 (ko) | 1990-02-27 | 1993-02-08 | 한미약품공업 주식회사 | 오메프라졸 직장투여 조성물 |
DK0475482T3 (da) | 1990-09-13 | 1995-04-03 | Akzo Nobel Nv | Stabiliserede faste kemiske midler |
GB9020959D0 (en) | 1990-09-26 | 1990-11-07 | Beecham Group Plc | Novel compounds |
US5084460A (en) * | 1990-12-24 | 1992-01-28 | A. H. Robins Company, Incorporated | Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides |
US5594003A (en) | 1991-02-06 | 1997-01-14 | Dr. Karl Thomae Gmbh | Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists |
US5602127A (en) | 1991-02-06 | 1997-02-11 | Karl Thomae Gmbh | (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists |
US5591762A (en) | 1991-02-06 | 1997-01-07 | Dr. Karl Thomae Gmbh | Benzimidazoles useful as angiotensin-11 antagonists |
GB9109862D0 (en) | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
DE4124150A1 (de) * | 1991-07-20 | 1993-01-21 | Bayer Ag | Substituierte triazole |
US5300298A (en) * | 1992-05-06 | 1994-04-05 | The Pennsylvania Research Corporation | Methods of treating obesity with purine related compounds |
GB9215633D0 (en) | 1992-07-23 | 1992-09-09 | Smithkline Beecham Plc | Novel treatment |
EP0581552B1 (de) * | 1992-07-31 | 1998-04-22 | Shionogi & Co., Ltd. | Triazolylthiomethylthiocephalosporin-Hydrochlorid, sein kristallines Hydrat und seine Herstellung |
TW252044B (de) * | 1992-08-10 | 1995-07-21 | Boehringer Ingelheim Kg | |
DE4242459A1 (de) * | 1992-12-16 | 1994-06-23 | Merck Patent Gmbh | Imidazopyridine |
EP0638567A4 (de) | 1993-02-18 | 1995-05-10 | Kyowa Hakko Kogyo Kk | Adenosin-aufnahme inhibitoren. |
JP3726291B2 (ja) | 1993-07-05 | 2005-12-14 | 三菱ウェルファーマ株式会社 | 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法 |
FR2707641B1 (fr) | 1993-07-16 | 1995-08-25 | Fournier Ind & Sante | Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique. |
DE4339868A1 (de) | 1993-11-23 | 1995-05-24 | Merck Patent Gmbh | Imidazopyridazine |
DE4404183A1 (de) | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-Amino-1-piperidylbenzoylguanidine |
US5545745A (en) * | 1994-05-23 | 1996-08-13 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
CO4410190A1 (es) | 1994-09-19 | 1997-01-09 | Lilly Co Eli | 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO |
AU699489B2 (en) | 1994-10-12 | 1998-12-03 | Euro-Celtique S.A. | Novel benzoxazoles |
GB9501178D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Guanine derivative |
WO1996036638A1 (en) | 1995-05-19 | 1996-11-21 | Chiroscience Limited | Xanthines and their therapeutic use |
JPH08333339A (ja) * | 1995-06-08 | 1996-12-17 | Fujisawa Pharmaceut Co Ltd | 光学活性なピペリジン酢酸誘導体の製造法 |
GB9523752D0 (en) | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
DE19543478A1 (de) | 1995-11-22 | 1997-05-28 | Bayer Ag | Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman |
FR2742751B1 (fr) * | 1995-12-22 | 1998-01-30 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
WO1997023447A1 (en) | 1995-12-26 | 1997-07-03 | Alteon Inc. | N-acylaminoalkylhydrazinecarboximidamides |
DE19616486C5 (de) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
US5965555A (en) * | 1996-06-07 | 1999-10-12 | Hoechst Aktiengesellschaft | Xanthine compounds having terminally animated alkynol side chains |
WO1997046526A1 (en) | 1996-06-07 | 1997-12-11 | Eisai Co., Ltd. | Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production |
US5958951A (en) * | 1996-06-14 | 1999-09-28 | Novo Nordiskials | Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride |
US5753635A (en) | 1996-08-16 | 1998-05-19 | Berlex Laboratories, Inc. | Purine derivatives and their use as anti-coagulants |
EA001881B1 (ru) | 1996-09-23 | 2001-10-22 | Эли Лилли Энд Компани | Форма d дигидрата оланзапина |
WO1998018770A1 (en) | 1996-10-28 | 1998-05-07 | Novo Nordisk A/S | A process for the preparation of (-)-3,4-trans-diarylchromans |
UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
DE69732572T2 (de) | 1996-11-12 | 2005-12-29 | Novo Nordisk A/S | Verwendung von glp-1 peptiden |
GB9623859D0 (en) | 1996-11-15 | 1997-01-08 | Chiroscience Ltd | Novel compounds |
CN1222315C (zh) | 1996-12-24 | 2005-10-12 | 拜奥根有限公司 | 稳定的液体干扰素制剂 |
DE19705233A1 (de) | 1997-02-12 | 1998-08-13 | Froelich Juergen C | Verfahren zur Herstellung einer Formulierung enthaltend Arginin |
US6011049A (en) | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
KR100563764B1 (ko) | 1997-03-13 | 2006-03-24 | 헥살 아게 | 아미노산과 시클로덱스트린과의 병용에 의한 산(酸) 민감성 벤즈이미다졸류의 안정화 방법 |
US5972332A (en) | 1997-04-16 | 1999-10-26 | The Regents Of The University Of Michigan | Wound treatment with keratinocytes on a solid support enclosed in a porous material |
CO4750643A1 (es) | 1997-06-13 | 1999-03-31 | Lilly Co Eli | Formulacion estable de la insulina que contiene l-arginina y protamina |
HUP0100280A3 (en) * | 1997-12-05 | 2003-03-28 | Astrazeneca Uk Ltd | Pyrrolo-, thieno-, furano- and pyrazolo- [3,4d]-pyridazinones, process for their preparation and pharmaceutical compositions containing them |
TW589174B (en) | 1997-12-10 | 2004-06-01 | Takeda Chemical Industries Ltd | Agent for treating high-risk impaired glucose tolerance |
JPH11193270A (ja) * | 1997-12-26 | 1999-07-21 | Koei Chem Co Ltd | 光学活性1−メチル−3−ピペリジンメタノールの製造方法 |
USRE39112E1 (en) * | 1998-01-05 | 2006-05-30 | Eisai Co., Ltd. | Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes |
EP2574336A1 (de) | 1998-02-02 | 2013-04-03 | Trustees Of Tufts College | Verwendung von Dipeptidylpeptidaseinhibitoren zur Regulierung des Glucosemetabolismus |
NZ506959A (en) | 1998-03-31 | 2002-02-01 | Nissan Chemical Ind Ltd | 3/2-hydrochloride of 4-chloro-5-[3-(4-benzylpiperazin-1-yl)carbonylmethoxy-4-methoxy benzylamino]-3(2H)-pyridazone |
EP0950658A1 (de) | 1998-04-13 | 1999-10-20 | Takeda Chemical Industries, Ltd. | 2-Piperazinone-1-acetic acid dihydrochloridderivat als Hemmer von Plättchenaggregation |
US6207207B1 (en) | 1998-05-01 | 2001-03-27 | Mars, Incorporated | Coated confectionery having a crispy starch based center and method of preparation |
DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
JP4748627B2 (ja) | 1998-07-15 | 2011-08-17 | 旭化成ケミカルズ株式会社 | 賦形剤 |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
IT1312018B1 (it) * | 1999-03-19 | 2002-04-04 | Fassi Aldo | Procedimento migliorato per la produzione di sali non igroscopicidella l(-)-carnitina. |
US20040152659A1 (en) | 1999-05-12 | 2004-08-05 | Fujisawa Pharmaceutical Co. Ltd. | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist |
AR023966A1 (es) | 1999-05-12 | 2002-09-04 | Fujisawa Pharmaceutical Co | Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion |
WO2000072799A2 (en) | 1999-05-27 | 2000-12-07 | The University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
KR100709909B1 (ko) * | 1999-06-21 | 2007-04-24 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 비사이클릭 헤테로사이클, 이를 함유하는 의약 조성물 및 이의 제조방법 |
US6448323B1 (en) | 1999-07-09 | 2002-09-10 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on polyvinyl alcohol |
ES2166270B1 (es) | 1999-07-27 | 2003-04-01 | Almirall Prodesfarma Sa | Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona. |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
AU777776B2 (en) | 1999-12-23 | 2004-10-28 | Novartis Ag | Use of hypoglycemic agent for treating impaired glucose metabolism |
JP2003519698A (ja) | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ,インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
US6362172B2 (en) | 2000-01-20 | 2002-03-26 | Bristol-Myers Squibb Company | Water soluble prodrugs of azole compounds |
DE122008000018I1 (de) | 2000-01-21 | 2008-08-14 | Novartis Pharma Ag | Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica |
JP4621326B2 (ja) | 2000-02-01 | 2011-01-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | テプレノンの安定化組成物 |
JP4739632B2 (ja) * | 2000-02-05 | 2011-08-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | Erkのインヒビターとして有用なピラゾール組成物 |
US20030040490A1 (en) | 2000-02-24 | 2003-02-27 | Yasuo Sugiyama | Drugs containing combined active ingredients |
EP1132389A1 (de) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | Neue Azaindolyl-Derivate für die Behandlung von Fettleibigheit |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
GB0006133D0 (en) | 2000-03-14 | 2000-05-03 | Smithkline Beecham Plc | Novel pharmaceutical |
JP2001278812A (ja) | 2000-03-27 | 2001-10-10 | Kyoto Pharmaceutical Industries Ltd | 錠剤用崩壊剤及びこれを用いた錠剤 |
CA2400226C (en) | 2000-03-31 | 2007-01-02 | Probiodrug Ag | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
JP2001292388A (ja) | 2000-04-05 | 2001-10-19 | Sharp Corp | 再生装置 |
GB0008694D0 (en) | 2000-04-07 | 2000-05-31 | Novartis Ag | Organic compounds |
JP2002193933A (ja) * | 2000-06-14 | 2002-07-10 | Toray Ind Inc | 光学活性ピペリジン誘導体またはその酸塩の製造方法 |
EP1295873A4 (de) | 2000-06-14 | 2004-05-19 | Verfahren zur herstellung racemischer piperidinderivate und zur herstellung optisch aktiver piperidinderivate | |
GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
US7078397B2 (en) | 2000-06-19 | 2006-07-18 | Smithkline Beecham Corporation | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
JP2004502690A (ja) | 2000-07-04 | 2004-01-29 | ノボ ノルディスク アクティーゼルスカブ | 酵素dpp−ivのインヒビターである複素環式化合物 |
US6448281B1 (en) * | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
WO2002014271A1 (fr) * | 2000-08-10 | 2002-02-21 | Mitsubishi Pharma Corporation | Dérivés de proline et leur utilisation comme médicaments |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
US20060034922A1 (en) | 2000-11-03 | 2006-02-16 | Andrx Labs, Llc | Controlled release metformin compositions |
JPWO2002051836A1 (ja) | 2000-12-27 | 2004-04-22 | 協和醗酵工業株式会社 | ジペプチジルペプチダーゼ−iv阻害剤 |
FR2819254B1 (fr) | 2001-01-08 | 2003-04-18 | Fournier Lab Sa | Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques |
DE10109021A1 (de) | 2001-02-24 | 2002-09-05 | Boehringer Ingelheim Pharma | Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE10117803A1 (de) | 2001-04-10 | 2002-10-24 | Boehringer Ingelheim Pharma | Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE60221098T2 (de) | 2001-02-02 | 2008-01-24 | Takeda Pharmaceutical Co. Ltd. | Kondensierte heterocyclische derivate |
US6649187B2 (en) | 2001-02-16 | 2003-11-18 | Bristol-Myers Squibb Pharma Company | Use of polyalkylamine polymers in controlled release devices |
US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
US6693094B2 (en) | 2001-03-22 | 2004-02-17 | Chrono Rx Llc | Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
JP2002348279A (ja) | 2001-05-25 | 2002-12-04 | Nippon Kayaku Co Ltd | 光学活性ピリジルケトン誘導体の製造方法並びに光学活性ピリジルケトン誘導体 |
DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
NZ529973A (en) | 2001-06-27 | 2006-01-27 | Smithkline Beecham Corp | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
EP1399433B1 (de) | 2001-06-27 | 2007-08-22 | Smithkline Beecham Corporation | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
EP1404675B1 (de) | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
EP1463727A2 (de) | 2001-09-19 | 2004-10-06 | Novo Nordisk A/S | Heterocyclische verbindungen, bei denen es sich um inhibitoren des enzyms dpp-iv handelt |
CN1568166A (zh) | 2001-10-15 | 2005-01-19 | 荷姆泰克股份有限公司 | 预防再狭窄的涂层支架 |
DE10151296A1 (de) | 2001-10-17 | 2003-04-30 | Boehringer Ingelheim Pharma | Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US20030083354A1 (en) | 2001-10-26 | 2003-05-01 | Pediamed Pharmaceuticals, Inc. | Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions |
US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
CA2363053C (en) | 2001-11-09 | 2011-01-25 | Bernard Charles Sherman | Clopidogrel bisulfate tablet formulation |
US20040171836A1 (en) | 2001-12-21 | 2004-09-02 | Toshihiro Fujino | Method for producing optical-active cis-piperidine derivatives |
JP2003342259A (ja) * | 2001-12-21 | 2003-12-03 | Toray Ind Inc | 光学活性シスピペリジン誘導体の製造法 |
US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
WO2003057200A2 (en) | 2002-01-11 | 2003-07-17 | Novo Nordisk A/S | Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
CZ303145B6 (cs) | 2002-01-16 | 2012-05-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Zpusob výroby dvojvrstevné farmaceutické tablety obsahující telmisartan a hydrochlorthiazid |
EP1333033A1 (de) | 2002-01-30 | 2003-08-06 | Boehringer Ingelheim Pharma GmbH & Co.KG | Mittels FAP aktivierbare anti-tumoröse Verbindungen |
KR20040079967A (ko) | 2002-02-01 | 2004-09-16 | 화이자 프로덕츠 인크. | 고체 약물 분산액을 함유하는 속방형 제형 |
US7610153B2 (en) | 2002-02-13 | 2009-10-27 | Virginia Commonwealth University | Multi-drug titration and evaluation |
PT1476138E (pt) | 2002-02-21 | 2012-02-14 | Valeant Internat Barbados Srl | Formulações de libertação modificada de pelo menos uma forma de tramadol |
DE60304911D1 (de) | 2002-02-25 | 2006-06-08 | Eisai Co Ltd | Xanthin-Derivate als DPP-IV-Inhibitoren |
HUP0200849A2 (hu) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
JP4298212B2 (ja) | 2002-03-29 | 2009-07-15 | 大日本印刷株式会社 | 塩酸エピナスチン高融点型結晶の製造法 |
JP2003300977A (ja) | 2002-04-10 | 2003-10-21 | Sumitomo Pharmaceut Co Ltd | キサンチン誘導体 |
AU2003226051A1 (en) | 2002-04-16 | 2003-11-03 | Banyu Pharmaceutical Co., Ltd. | Solid forms of salts with tyrosine kinase activity |
WO2003090783A1 (fr) | 2002-04-26 | 2003-11-06 | Ajinomoto Co., Inc. | Agent preventif/remede pour diabete |
AU2003231252A1 (en) | 2002-05-09 | 2003-11-11 | Enos Pharmaceuticals, Inc. | Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease |
GB0212412D0 (en) | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
DK1509525T5 (da) * | 2002-05-31 | 2007-07-30 | Schering Corp | Fremgangsmåde til fremstilling af xanthin-phosphodiesterase V-inhibitorer og præcursorer derfor |
EP1514552A4 (de) * | 2002-06-06 | 2008-04-02 | Eisai R&D Man Co Ltd | Neues kondensiertes imidazolderivativ |
FR2840897B1 (fr) | 2002-06-14 | 2004-09-10 | Fournier Lab Sa | Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique |
US20040002615A1 (en) * | 2002-06-28 | 2004-01-01 | Allen David Robert | Preparation of chiral amino-nitriles |
US20040023981A1 (en) | 2002-07-24 | 2004-02-05 | Yu Ren | Salt forms with tyrosine kinase activity |
TW200409746A (en) | 2002-07-26 | 2004-06-16 | Theravance Inc | Crystalline β2 adrenergic receptor agonist |
TW200404796A (en) | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
US7407955B2 (en) * | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
DE10238243A1 (de) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
DE10238477A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
DE10238470A1 (de) * | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US7569574B2 (en) * | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7495005B2 (en) | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
WO2004024184A1 (ja) | 2002-09-11 | 2004-03-25 | Takeda Pharmaceutical Company Limited | 徐放性製剤 |
BR0314356A (pt) | 2002-09-16 | 2005-07-19 | Wyeth Corp | Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas |
BR0314655A (pt) | 2002-09-26 | 2005-08-02 | Eisai Co Ltd | Droga de combinação |
AU2003267732A1 (en) | 2002-10-08 | 2004-05-04 | Ranbaxy Laboratories Limited | Gabapentin tablets and methods for their preparation |
AU2003269850A1 (en) | 2002-10-08 | 2004-05-04 | Novo Nordisk A/S | Hemisuccinate salts of heterocyclic dpp-iv inhibitors |
US20040122048A1 (en) | 2002-10-11 | 2004-06-24 | Wyeth Holdings Corporation | Stabilized pharmaceutical composition containing basic excipients |
US6861526B2 (en) * | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
CA2502269C (en) | 2002-10-18 | 2009-12-22 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
JP2004161749A (ja) * | 2002-10-24 | 2004-06-10 | Toray Fine Chemicals Co Ltd | 光学活性含窒素化合物の製造方法 |
AU2003280680A1 (en) | 2002-11-01 | 2004-06-18 | Sumitomo Pharmaceuticals Co., Ltd. | Xanthine compound |
BR0315796A (pt) | 2002-11-07 | 2005-09-13 | Merck & Co Inc | Composto, composição farmacêutica, e, métodos para tratar diabetes, para tratar hiperglicemia, e para tratar obesidade em um mamìfero |
US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
DE10254304A1 (de) * | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US7109192B2 (en) * | 2002-12-03 | 2006-09-19 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions |
UY28103A1 (es) | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos |
AU2003294824A1 (en) | 2002-12-10 | 2004-06-30 | Novartis Ag | Combination of an dpp-iv inhibitor and a ppar-alpha compound |
US20040152720A1 (en) | 2002-12-20 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powdered medicaments containing a tiotropium salt and salmeterol xinafoate |
DE10351663A1 (de) | 2002-12-20 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat |
SI1599222T1 (sl) | 2003-01-08 | 2009-08-31 | Novartis Vaccines & Diagnostic | Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja |
ES2295816T3 (es) | 2003-01-14 | 2008-04-16 | Arena Pharmaceuticals, Inc. | Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia. |
DE10335027A1 (de) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
JP2004250336A (ja) | 2003-02-18 | 2004-09-09 | Kao Corp | コーティング錠及び糖衣錠の製造法 |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7442387B2 (en) | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
CA2515289A1 (en) | 2003-03-12 | 2004-09-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Weak base salts |
AU2004222633B2 (en) | 2003-03-18 | 2008-05-01 | Nestec S.A. | Compositions comprising fatty acids and amino acids |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
JPWO2004096806A1 (ja) | 2003-04-30 | 2006-07-13 | 大日本住友製薬株式会社 | 縮合イミダゾール誘導体 |
TW200510277A (en) | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
AU2003902828A0 (en) | 2003-06-05 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
US7566707B2 (en) * | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
DE10327439A1 (de) | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
KR100744893B1 (ko) | 2003-06-20 | 2007-08-01 | 에프. 호프만-라 로슈 아게 | Dpp-iv 저해제로서 헥사하이드로피리도아이소퀴놀린 |
BRPI0411713B8 (pt) | 2003-06-20 | 2021-05-25 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização |
JO2625B1 (en) | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
CA2532971A1 (en) | 2003-07-14 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
US20050027012A1 (en) | 2003-07-16 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Tablets containing ambroxol |
DE60331236D1 (de) | 2003-07-24 | 2010-03-25 | Eswaran Krishnan Iyer | Orale zusammensetzungen zur behandlung von diabetes |
US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
BRPI0413234A (pt) | 2003-08-01 | 2006-10-03 | Genelabs Tech Inc | derivados de imidazola bicìclica contra flaviviridae |
EP2226072A1 (de) | 2003-08-29 | 2010-09-08 | Aton Pharma, Inc. | Kombinationen aus Suberoylanilid-Hydroxyaminsäure und Antimetabolika zur Behandlung von Krebs |
EP1699777B1 (de) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidylpeptidase-hemmer |
CA2540741A1 (en) | 2003-10-03 | 2005-04-14 | Takeda Pharmaceutical Company Limited | Agent for treating diabetes |
BR0304443B1 (pt) | 2003-10-28 | 2012-08-21 | processo para obtenção de concentrados de titánio com elevado teor de tio2 e baixo teor de radionuclìdeos a partir de concentrados mecánicos de anatásio. | |
US7107714B2 (en) | 2003-11-10 | 2006-09-19 | Marketing Displays, Inc. | Portable snap-fit sign stand |
WO2005049022A2 (en) | 2003-11-17 | 2005-06-02 | Novartis Ag | Use of dipeptidyl peptidase iv inhibitors |
DE10355304A1 (de) * | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
WO2005053695A1 (ja) * | 2003-12-04 | 2005-06-16 | Eisai Co., Ltd. | 多発性硬化症予防剤または治療剤 |
DE10359098A1 (de) | 2003-12-17 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel |
US7217711B2 (en) * | 2003-12-17 | 2007-05-15 | Boehringer Ingelheim International Gmbh | Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions |
BRPI0417668A (pt) * | 2003-12-18 | 2007-04-03 | Tibotec Pharm Ltd | derivados de piperidina-amino-benzimidazol como inibidores de replicação do vìrus sincicial respiratório |
DE10360835A1 (de) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
NZ547965A (en) | 2003-12-24 | 2009-12-24 | Prosidion Ltd | 1,2,4-Oxadiazole derivatives as GPCR receptor agonists |
US20080234291A1 (en) | 2004-01-21 | 2008-09-25 | Marc Karel Jozef Francois | Mitratapide Oral Solution |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004019540A1 (de) | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen |
DE102004009039A1 (de) | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
EP1593671A1 (de) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV Inhibitoren |
US7393847B2 (en) * | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
CN102134230B (zh) | 2004-03-15 | 2019-06-28 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
EP2360165A3 (de) | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
EP1577306A1 (de) | 2004-03-17 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
US7179809B2 (en) | 2004-04-10 | 2007-02-20 | Boehringer Ingelheim International Gmbh | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions |
CA2561210A1 (en) | 2004-04-10 | 2005-10-20 | Boehringer Ingelheim International Gmbh | Novel 2-amino-imidazo[4,5-d]pyridazin-4-ones and 2-amino-imidazo[4,5-c]pyridin-4-ones, production and use thereof as medicaments |
US20050239778A1 (en) | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim International Gmbh | Novel medicament combinations for the treatment of respiratory diseases |
US20050244502A1 (en) | 2004-04-28 | 2005-11-03 | Mathias Neil R | Composition for enhancing absorption of a drug and method |
US7439370B2 (en) * | 2004-05-10 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
EP1753748B1 (de) | 2004-05-12 | 2009-07-29 | Pfizer Products Inc. | Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren |
DE102004024454A1 (de) | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
PE20060315A1 (es) | 2004-05-24 | 2006-05-15 | Irm Llc | Compuestos de tiazol como moduladores de ppar |
TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
UA93349C2 (ru) | 2004-06-01 | 2011-02-10 | Эйрэс Трейдинг C.A. | Способ стабилизации мономерного белка интерферона |
US7935723B2 (en) | 2004-06-04 | 2011-05-03 | Novartis Pharma Ag | Use of organic compounds |
WO2005120576A2 (en) | 2004-06-09 | 2005-12-22 | Yasoo Health | Composition and method for improving pancreatic islet cell survival |
DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
US20080269311A1 (en) | 2004-07-14 | 2008-10-30 | Edwin Bernard Villhauer | Combination of Dpp-Iv Inhibitors and Compounds Modulating 5-Ht3 and/or 5-Ht4 Receptors |
TW200613275A (en) | 2004-08-24 | 2006-05-01 | Recordati Ireland Ltd | Lercanidipine salts |
JP4854511B2 (ja) | 2004-08-26 | 2012-01-18 | 武田薬品工業株式会社 | 糖尿病治療剤 |
DE102004043944A1 (de) | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
DE102004044221A1 (de) | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
CN1759834B (zh) | 2004-09-17 | 2010-06-23 | 中国医学科学院医药生物技术研究所 | 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途 |
CA2580461A1 (en) | 2004-09-23 | 2006-04-06 | Amgen Inc. | Substituted sulfonamidopropionamides and methods of use |
CN101035536A (zh) | 2004-10-08 | 2007-09-12 | 诺瓦提斯公司 | 有机化合物的组合 |
WO2006040625A1 (en) | 2004-10-12 | 2006-04-20 | Glenmark Pharmaceuticals S.A. | Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation |
WO2006047248A1 (en) | 2004-10-25 | 2006-05-04 | Novartis Ag | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
DE102005013967A1 (de) | 2004-11-05 | 2006-10-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
TW200635930A (en) | 2004-12-24 | 2006-10-16 | Dainippon Sumitomo Pharma Co | Bicyclic pyrrole derivatives |
KR100760430B1 (ko) | 2004-12-31 | 2007-10-04 | 한미약품 주식회사 | 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법 |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
GT200600008A (es) | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
JP2008536881A (ja) | 2005-04-21 | 2008-09-11 | ガストロテック・ファルマ・アクティーゼルスカブ | Glp−1分子と制吐剤との医薬製剤 |
WO2006116157A2 (en) | 2005-04-22 | 2006-11-02 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-iv inhibitors |
WO2006114923A1 (ja) | 2005-04-25 | 2006-11-02 | Hitachi, Ltd. | 磁気共鳴を用いた検査装置および核磁気共鳴信号受信用コイル |
UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
WO2006127207A1 (en) | 2005-05-25 | 2006-11-30 | Wyeth | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof |
GT200600218A (es) | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
BRPI0612301A2 (pt) | 2005-06-20 | 2009-01-27 | Decode Genetics Ehf | mÉtodo para diagnosticar uma suscetibilidade para a diabete tipo ii em um indivÍduo, kit, e, mÉtodo para avaliar um indivÍduo quanto a probabilidade de resposta a um agente terapÊutico de tcf7l2 |
ATE483732T1 (de) | 2005-07-08 | 2010-10-15 | Pfizer Ltd | Madcam-antikörper |
UY29694A1 (es) | 2005-07-28 | 2007-02-28 | Boehringer Ingelheim Int | Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
BRPI0614732A2 (pt) | 2005-08-11 | 2011-04-12 | Hoffmann La Roche | composição farmacêutica que compreende um inibidor de dpp-iv, uso de um inibidor de dpp-iv e método para o tratamento de enfermidades associadas com nìveis de glicose sanguìnea elevados |
EP1760076A1 (de) | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitoren |
SI1942898T2 (sl) | 2005-09-14 | 2014-08-29 | Takeda Pharmaceutical Company Limited | Dipeptidil-peptidazni inhibitorji za zdravljenje diabetesa |
MX2008003634A (es) | 2005-09-16 | 2009-10-08 | Arena Pharm Inc | Moduladores del metabolismo y tratamiento de los trastornos metabolicos. |
AU2006292377B2 (en) | 2005-09-20 | 2011-03-03 | Emisphere Technologies, Inc. | Use of a DPP-IV inhibitor to reduce hypoglycemic events |
JOP20180109A1 (ar) | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
WO2007050485A2 (en) | 2005-10-25 | 2007-05-03 | Merck & Co., Inc. | Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
EP1943301A4 (de) | 2005-11-04 | 2010-01-13 | Ls Corp | Synthese von mdh-polymer-hybridteilchen |
US8414921B2 (en) | 2005-12-16 | 2013-04-09 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
BRPI0620643A2 (pt) | 2005-12-23 | 2011-12-20 | Novartis Ag | compostos de heterocìclicos condensados úteis como inibidores de dpp-iv, formulações farmacêuticas, produtos e usos dos compostos |
WO2007120936A2 (en) | 2006-01-06 | 2007-10-25 | Novartis Ag | Use.of vildagliptin for the treatment of diabetes |
KR20080102395A (ko) | 2006-02-15 | 2008-11-25 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코피라노실-치환된 벤조니트릴 유도체, 당해 화합물을 함유하는 약제학적 조성물, 이들의 용도 및 이들의 제조방법 |
WO2007099345A1 (en) | 2006-03-02 | 2007-09-07 | Betagenon Ab | Medical use of bmp-2 and/ or bmp-4 |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
US8455435B2 (en) | 2006-04-19 | 2013-06-04 | Ludwig-Maximilians-Universitat Munchen | Remedies for ischemia |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
JP5323684B2 (ja) | 2006-05-04 | 2013-10-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 多形体 |
KR20070111099A (ko) | 2006-05-16 | 2007-11-21 | 영진약품공업주식회사 | 시타글립틴 염산염의 신규 결정형, 이의 제조 방법과 이를포함하는 약학적 조성물 |
WO2007136650A2 (en) | 2006-05-16 | 2007-11-29 | Gilead Sciences, Inc. | Method and compositions for treating hematological malignancies |
US20080064717A1 (en) | 2006-05-19 | 2008-03-13 | Rajesh Iyengar | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme |
KR100858848B1 (ko) | 2006-05-23 | 2008-09-17 | 한올제약주식회사 | 메트포르민 서방정 |
WO2007149797A2 (en) | 2006-06-19 | 2007-12-27 | Novartis Ag | Use of organic compounds |
WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
AT503443B1 (de) | 2006-06-23 | 2007-10-15 | Leopold Franzens Uni Innsbruck | Verfahren zur herstellung einer eisfläche für eissportbahnen |
TW200811140A (en) | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
TW200811147A (en) | 2006-07-06 | 2008-03-01 | Arena Pharm Inc | Modulators of metabolism and the treatment of disorders related thereto |
US8071583B2 (en) | 2006-08-08 | 2011-12-06 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus |
US8039441B2 (en) | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
AU2007285827A1 (en) | 2006-08-17 | 2008-02-21 | Wellstat Therapeutics Corporation | Combination treatment for metabolic disorders |
DE102006042586B4 (de) | 2006-09-11 | 2014-01-16 | Betanie B.V. International Trading | Verfahren zum mikropartikulären Beladen von hochpolymeren Kohlenhydraten mit hydrophoben Wirkflüssigkeiten |
US7956201B2 (en) | 2006-11-06 | 2011-06-07 | Hoffman-La Roche Inc. | Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one |
EP2079753A1 (de) | 2006-11-06 | 2009-07-22 | Boehringer Ingelheim International GmbH | Glucopyranosylsubstituierte benzylbenzonitrilderivate, medikamente, die diese verbindungen enthalten, ihre verwendung und verfahren zu ihrer herstellung |
EP3037095A3 (de) | 2006-11-09 | 2016-11-16 | Boehringer Ingelheim International GmbH | Kombinationstherapie mit sglt-2-inhibitoren und deren pharmazeutische zusammensetzungen |
WO2008070692A2 (en) | 2006-12-06 | 2008-06-12 | Smithkline Beecham Corporation | Bicyclic compounds and use as antidiabetics |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
CL2008000017A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
CL2008000133A1 (es) | 2007-01-19 | 2008-05-23 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e |
TW201350143A (zh) | 2007-02-01 | 2013-12-16 | Takeda Pharmaceutical | 固體型製劑 |
EP2124901B1 (de) | 2007-02-01 | 2017-07-19 | Takeda Pharmaceutical Company Limited | Tablettenherstellung ohne verursachung von tablettierdefekten |
WO2008113000A1 (en) | 2007-03-15 | 2008-09-18 | Nectid, Inc. | Anti-diabetic combinations comprising a slow release biguanide composition and an immediate release dipeptidyl peptidase iv inhibitor composition |
KR20120030570A (ko) | 2007-04-03 | 2012-03-28 | 미쓰비시 타나베 파마 코퍼레이션 | 디펩티딜 펩티다아제 4 저해 화합물과 감미료와의 병용 |
EP2142113B1 (de) | 2007-04-16 | 2023-01-11 | Smith & Nephew, Inc. | Elektrisch betriebenes chirurgisches system |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
JP2010526145A (ja) | 2007-05-04 | 2010-07-29 | ブリストル−マイヤーズ スクイブ カンパニー | [6,6]および[6,7]−二環式gpr119gタンパク質結合受容体アゴニスト |
US8440172B2 (en) | 2007-07-09 | 2013-05-14 | Symrise Ag | Stable soluble salts of phenylbenzimidazole sulfonic acid at PHS at or below 7.0 |
NZ583346A (en) | 2007-07-19 | 2012-02-24 | Takeda Pharmaceutical | Solid preparation comprising alogliptin and metformin hydrochloride |
UY31290A1 (es) | 2007-08-16 | 2009-03-31 | Composicion farmacéutica que comprende un derivado de pirazol-o-glucosido | |
PE20090597A1 (es) | 2007-08-16 | 2009-06-06 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
CL2008002425A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta. |
JP5769966B2 (ja) | 2007-08-17 | 2015-08-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Fab関連疾患治療用プリン誘導体 |
WO2009037719A1 (en) | 2007-09-21 | 2009-03-26 | Lupin Limited | Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors |
MX2010005245A (es) | 2007-11-16 | 2010-06-01 | Novo Nordisk As | Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal. |
CN101234105A (zh) | 2008-01-09 | 2008-08-06 | 北京润德康医药技术有限公司 | 一种含有二甲双胍和维格列汀的药用组合物及其制备方法 |
US20090186086A1 (en) | 2008-01-17 | 2009-07-23 | Par Pharmaceutical, Inc. | Solid multilayer oral dosage forms |
TW200936136A (en) | 2008-01-28 | 2009-09-01 | Sanofi Aventis | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application |
JP2011510986A (ja) | 2008-02-05 | 2011-04-07 | メルク・シャープ・エンド・ドーム・コーポレイション | メトホルミン及びジペプチジルペプチダーゼ−iv阻害剤の併用医薬組成物 |
EP2259676A4 (de) | 2008-03-04 | 2011-03-16 | Merck Sharp & Dohme | Pharmazeutische zusammensetzungen aus einer kombination von metformin und einem dipeptidyl-peptidase-iv-hemmer |
CA2717138A1 (en) | 2008-03-05 | 2009-09-11 | Takeda Pharmaceutical Company Limited | 5-membered heterocyclic compounds and bicyclic heteroaryl having glucagon antagonistic action useful for treating diabetes |
US8551524B2 (en) | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
CA2719507C (en) | 2008-03-31 | 2018-03-27 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
PE20100156A1 (es) | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
EP2326326B1 (de) | 2008-08-15 | 2019-10-09 | Boehringer Ingelheim International GmbH | Dpp-4 inhibitoren zur verwendung in der wundheilung von diabetes-patienten |
JP2010053576A (ja) | 2008-08-27 | 2010-03-11 | Sumitomo Forestry Co Ltd | 舗装用マット |
CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
UY32177A (es) | 2008-10-16 | 2010-05-31 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético |
WO2010045656A2 (en) | 2008-10-17 | 2010-04-22 | Nectid, Inc. | Novel sglt2 inhibitor dosage forms |
CN107011345A (zh) | 2008-12-23 | 2017-08-04 | 勃林格殷格翰国际有限公司 | 有机化合物的盐形式 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
CN117547538A (zh) | 2009-02-13 | 2024-02-13 | 勃林格殷格翰国际有限公司 | 包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物 |
SG173619A1 (en) | 2009-02-13 | 2011-09-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
TW201031661A (en) | 2009-02-17 | 2010-09-01 | Targacept Inc | Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands |
EP2408780A2 (de) | 2009-03-20 | 2012-01-25 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonane |
US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
WO2010140111A1 (en) | 2009-06-02 | 2010-12-09 | Ranbaxy Laboratories Limited | Pharmaceutical compositions containing a combination of an antihistamine and a decongestant |
WO2010147768A1 (en) | 2009-06-15 | 2010-12-23 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
RU2733410C2 (ru) | 2009-07-21 | 2020-10-01 | Керикс Байофармасьютикалз, Инк. | Лекарственные формы цитрата железа (iii) |
BR112012007234A2 (pt) | 2009-10-02 | 2016-04-05 | Boehringer Ingelheim Int | combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
EP2504002B1 (de) | 2009-11-27 | 2019-10-09 | Boehringer Ingelheim International GmbH | Behandlung von genotypisierten diabetes-patienten mit dpp-iv-hemmern wie etwa linagliptin |
JP2010070576A (ja) | 2009-12-28 | 2010-04-02 | Sato Pharmaceutical Co Ltd | 速溶解性錠剤 |
US20130109703A1 (en) | 2010-03-18 | 2013-05-02 | Boehringer Ingelheim International Gmbh | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions |
EP2566464A1 (de) | 2010-05-05 | 2013-03-13 | Boehringer Ingelheim International GmbH | Pharmazeutische formulierungen mit pioglitazon und linagliptin |
MX341025B (es) | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
AR084698A1 (es) | 2010-06-22 | 2013-06-05 | Twi Pharmaceuticals Inc | Composiciones de liberacion controlada con reducido efecto de alimentos, reducida interaccion entre farmaco y los alimentos |
NZ603319A (en) | 2010-06-24 | 2015-04-24 | Boehringer Ingelheim Int | Diabetes therapy |
EP2611442B1 (de) | 2010-09-03 | 2018-07-04 | Bristol-Myers Squibb Company | Wirkstoffformulierungen mit waserlöslichen antioxidanzien |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
WO2012088682A1 (en) | 2010-12-29 | 2012-07-05 | Shanghai Fochon Pharmaceutical Co Ltd. | 2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors |
EP2670397B1 (de) | 2011-02-01 | 2020-05-13 | Bristol-Myers Squibb Company | Pharmazeutische formulierungen mit einer aminverbindung |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
EA023330B1 (ru) | 2011-05-10 | 2016-05-31 | Сандоз Аг | Полиморфная форма бензоата линаглиптина |
PL2731947T3 (pl) | 2011-07-15 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II |
US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
MX353496B (es) | 2012-01-04 | 2018-01-16 | Procter & Gamble | Estructuras fibrosas que contienen activos con múltiples regiones. |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
ES2929025T3 (es) | 2012-05-14 | 2022-11-24 | Boehringer Ingelheim Int | Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP2854812A1 (de) | 2012-05-24 | 2015-04-08 | Boehringer Ingelheim International GmbH | Xanthinderivat als dpp-4-inhibitor zur behandlung von autoimmundiabetes, insbesondere lada |
EP2854824A1 (de) | 2012-05-25 | 2015-04-08 | Boehringer Ingelheim International GmbH | Verwendung von keratinozyten als einer biologisch aktive substanz in der behandlung von wunden wie diabätische wunden, gegebenenfalls in kombination mit einem dpp-4-hemmer |
WO2013179307A2 (en) | 2012-05-29 | 2013-12-05 | Mylan Laboratories Limited | Stabilized pharmaceutical compositions of saxagliptin |
EP2908806A1 (de) | 2012-10-09 | 2015-08-26 | Boehringer Ingelheim International GmbH | Verwendung von selektiv feuchtigkeitsadaptiertem tablettierungsmaterial bei der herstellung mechanisch stabiler tabletten mit wenigstens einem hydratbildenden wirkstoff und/oder adjuvans hinsichtlich der mechanischen stabilität der tabletten, insbesondere argininhaltiger tabletten |
US20140100292A1 (en) | 2012-10-09 | 2014-04-10 | Boehringer Ingelheim International Gmbh | Use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolving kinetics and/or the water loading of the tablets |
JP2016510795A (ja) | 2013-03-15 | 2016-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
WO2014184376A1 (en) | 2013-05-17 | 2014-11-20 | Boehringer Ingelheim International Gmbh | Combination of a dpp-4 inhibitor and an alpha-glucosidase inhibitor |
WO2014198906A1 (en) | 2013-06-14 | 2014-12-18 | Boehringer Ingelheim International Gmbh | Dpp-4 inhibitors for treating diabetes and its complications |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
US20160106677A1 (en) | 2014-10-17 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
-
2004
- 2004-11-05 DE DE102004054054A patent/DE102004054054A1/de not_active Withdrawn
-
2005
- 2005-11-02 UA UAA200705849 patent/UA100221C2/xx unknown
- 2005-11-02 EP EP10181043.0A patent/EP2287164B9/de active Active
- 2005-11-02 EA EA200700974A patent/EA012163B1/ru not_active IP Right Cessation
- 2005-11-02 PL PL10181043T patent/PL2287164T3/pl unknown
- 2005-11-02 KR KR1020147013135A patent/KR101583264B1/ko not_active Application Discontinuation
- 2005-11-02 KR KR1020127034452A patent/KR101440796B1/ko active IP Right Grant
- 2005-11-02 WO PCT/EP2005/055711 patent/WO2006048427A1/de active Application Filing
- 2005-11-02 CN CN201110002001.6A patent/CN102127080B/zh active Active
- 2005-11-02 SG SG2013026703A patent/SG189768A1/en unknown
- 2005-11-02 CN CN200580037243.1A patent/CN101048409B/zh active Active
- 2005-11-02 CN CN201710405988.3A patent/CN107266449B/zh active Active
- 2005-11-02 EP EP05804601A patent/EP1812438A1/de not_active Withdrawn
- 2005-11-02 DK DK15200579.9T patent/DK3029040T3/da active
- 2005-11-02 HU HUE15200579 patent/HUE044308T2/hu unknown
- 2005-11-02 BR BRPI0517093A patent/BRPI0517093B8/pt active IP Right Grant
- 2005-11-02 RS RS20140080A patent/RS53166B/en unknown
- 2005-11-02 PT PT101810430T patent/PT2287164E/pt unknown
- 2005-11-02 TR TR2019/08974T patent/TR201908974T4/tr unknown
- 2005-11-02 NZ NZ555324A patent/NZ555324A/en unknown
- 2005-11-02 NZ NZ589450A patent/NZ589450A/en unknown
- 2005-11-02 AU AU2005300559A patent/AU2005300559B2/en active Active
- 2005-11-02 CA CA2586938A patent/CA2586938C/en active Active
- 2005-11-02 JP JP2007539576A patent/JP5063356B2/ja active Active
- 2005-11-02 CN CN2011103540629A patent/CN102391267A/zh active Pending
- 2005-11-02 MY MYPI20055194A patent/MY145604A/en unknown
- 2005-11-02 EA EA200900536A patent/EA016752B1/ru not_active IP Right Cessation
- 2005-11-02 CN CN2011103551125A patent/CN102432593A/zh active Pending
- 2005-11-02 CN CN201310264236.1A patent/CN103351388B/zh active Active
- 2005-11-02 DK DK10181043.0T patent/DK2287164T5/da active
- 2005-11-02 NZ NZ617916A patent/NZ617916A/en unknown
- 2005-11-02 ES ES10181043.0T patent/ES2458106T3/es active Active
- 2005-11-02 EP EP15200579.9A patent/EP3029040B1/de active Active
- 2005-11-02 SG SG200907377-6A patent/SG157371A1/en unknown
- 2005-11-02 MX MX2011008031A patent/MX344285B/es unknown
- 2005-11-02 SG SG2012082111A patent/SG185967A1/en unknown
- 2005-11-02 ME MEP-2014-21A patent/ME01667B/me unknown
- 2005-11-02 EP EP19166570.2A patent/EP3539956A1/de active Pending
- 2005-11-02 PL PL15200579T patent/PL3029040T3/pl unknown
- 2005-11-02 EA EA201200491A patent/EA029039B1/ru not_active IP Right Cessation
- 2005-11-02 ES ES15200579T patent/ES2731334T3/es active Active
- 2005-11-02 MX MX2007005404A patent/MX2007005404A/es active IP Right Grant
- 2005-11-02 SI SI200531835T patent/SI2287164T1/sl unknown
- 2005-11-02 KR KR1020077012615A patent/KR101383610B1/ko active IP Right Grant
- 2005-11-03 PE PE2010000005A patent/PE20100232A1/es not_active Application Discontinuation
- 2005-11-03 UY UY29190A patent/UY29190A1/es not_active Application Discontinuation
- 2005-11-03 PE PE2005001286A patent/PE20060921A1/es not_active Application Discontinuation
- 2005-11-04 TW TW094138684A patent/TWI374885B/zh not_active IP Right Cessation
- 2005-11-04 US US11/267,235 patent/US7820815B2/en active Active
- 2005-11-04 TW TW101117498A patent/TW201305166A/zh unknown
- 2005-11-04 AR ARP050104625A patent/AR051947A1/es unknown
-
2007
- 2007-03-07 ZA ZA200701996A patent/ZA200701996B/xx unknown
- 2007-03-23 NO NO20071522A patent/NO20071522L/no not_active Application Discontinuation
- 2007-05-02 IL IL182923A patent/IL182923A/en active IP Right Grant
-
2008
- 2008-03-31 HK HK08103534.9A patent/HK1109405A1/xx not_active IP Right Cessation
-
2009
- 2009-03-30 US US12/413,851 patent/US8541450B2/en active Active
-
2011
- 2011-02-02 IL IL211015A patent/IL211015A0/en unknown
- 2011-05-30 JP JP2011120229A patent/JP5947492B2/ja active Active
-
2012
- 2012-06-29 JP JP2012147088A patent/JP5766661B2/ja active Active
-
2013
- 2013-03-01 US US13/782,149 patent/US8883805B2/en active Active
-
2014
- 2014-04-14 CY CY20141100273T patent/CY1115036T1/el unknown
- 2014-04-22 HR HRP20140373TT patent/HRP20140373T2/hr unknown
- 2014-10-06 US US14/507,190 patent/US9499546B2/en active Active
-
2016
- 2016-10-11 US US15/290,454 patent/US20170029402A1/en not_active Abandoned
-
2017
- 2017-01-25 US US15/414,694 patent/US9751855B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4005208A (en) * | 1975-05-16 | 1977-01-25 | Smithkline Corporation | N-Heterocyclic-9-xanthenylamines |
WO2002068420A1 (de) * | 2001-02-24 | 2002-09-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthinderivate, deren herstellung und deren verwendung als arzneimittel |
WO2004018468A2 (de) * | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als arzneimittel |
WO2004041820A1 (de) * | 2002-11-08 | 2004-05-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel |
WO2005085246A1 (de) * | 2004-02-18 | 2005-09-15 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthine, deren herstellung und deren verwendung als dpp-iv hemmer |
JP2006045156A (ja) * | 2004-08-06 | 2006-02-16 | Sumitomo Pharmaceut Co Ltd | 縮合ピラゾール誘導体 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1812438A1 * |
Cited By (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9108964B2 (en) | 2002-08-21 | 2015-08-18 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8664232B2 (en) | 2002-08-21 | 2014-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US10023574B2 (en) | 2002-08-21 | 2018-07-17 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9556175B2 (en) | 2002-08-21 | 2017-01-31 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions |
US10202383B2 (en) | 2002-08-21 | 2019-02-12 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8119648B2 (en) | 2002-08-21 | 2012-02-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8178541B2 (en) | 2002-08-21 | 2012-05-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9321791B2 (en) | 2002-08-21 | 2016-04-26 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7838529B2 (en) | 2002-08-22 | 2010-11-23 | Boehringer Ingelheim International Gmbh | Xanthine derivates, their preparation and their use in pharmaceutical compositions |
US7696212B2 (en) | 2002-11-08 | 2010-04-13 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US8034941B2 (en) | 2003-06-18 | 2011-10-11 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US8697868B2 (en) | 2004-02-18 | 2014-04-15 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US7645763B2 (en) | 2004-02-23 | 2010-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition |
US7667035B2 (en) | 2004-05-10 | 2010-02-23 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
US7906539B2 (en) | 2004-06-24 | 2011-03-15 | Boehringer Ingelheim International Gmbh | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US8541450B2 (en) | 2004-11-05 | 2013-09-24 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines |
US8883805B2 (en) | 2004-11-05 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US9751855B2 (en) | 2004-11-05 | 2017-09-05 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US7820815B2 (en) | 2004-11-05 | 2010-10-26 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines |
US9499546B2 (en) | 2004-11-05 | 2016-11-22 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
EP2540724A1 (de) * | 2005-07-30 | 2013-01-02 | Boehringer Ingelheim International GmbH | Hydrochloride und Hydrate von 1-[(3-cyano-pyridin-2-yl) methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-amino-piperidin-1-yl)-xanthin, deren Herstellung und deren Verwendung als Arzneimittel |
WO2007014886A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Hydrochloride und hydrate von 1-[(3-cyano-pyridin-2-yl) methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-amino-piperidin-1-yl)-xanthin, deren herstellung und deren verwendung als arzneimittel |
CN101233133B (zh) * | 2005-07-30 | 2011-09-07 | 贝林格尔·英格海姆国际有限公司 | 1-[(3-氰基-吡啶-2-基)甲基]-3-甲基-7-(2-丁炔-1-基)-8-(3-氨基-哌啶-1-基)-黄嘌呤的盐酸盐及水合物、其制备方法及其作为药物的用途 |
US8637530B2 (en) | 2005-07-30 | 2014-01-28 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
EA013411B1 (ru) * | 2005-07-30 | 2010-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Гидрохлориды 1-[(3-цианопиридин-2-ил)метил]-3-метил-7-(2-бутин-1-ил)-8-(3-аминопиперидин-1-ил)ксантина, их получение и их применение в качестве лекарственных средств |
US8106060B2 (en) | 2005-07-30 | 2012-01-31 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
US9173859B2 (en) | 2006-05-04 | 2015-11-03 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US9815837B2 (en) | 2006-05-04 | 2017-11-14 | Boehringer Ingelheim International Gmbh | Polymorphs |
US8232281B2 (en) | 2006-05-04 | 2012-07-31 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
US10080754B2 (en) | 2006-05-04 | 2018-09-25 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US10301313B2 (en) | 2006-05-04 | 2019-05-28 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9493462B2 (en) | 2006-05-04 | 2016-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
US11084819B2 (en) | 2006-05-04 | 2021-08-10 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9266888B2 (en) | 2006-05-04 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Polymorphs |
EP2016079A1 (de) | 2006-05-04 | 2009-01-21 | Boehringer Ingelheim International GmbH | Polymorphe |
US8673927B2 (en) | 2006-05-04 | 2014-03-18 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
US11291668B2 (en) | 2006-05-04 | 2022-04-05 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US11919903B2 (en) | 2006-05-04 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Polymorphs |
US8071583B2 (en) | 2006-08-08 | 2011-12-06 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus |
US8551957B2 (en) | 2007-08-16 | 2013-10-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
WO2009022007A1 (en) | 2007-08-16 | 2009-02-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative |
EP3939577A1 (de) | 2007-08-16 | 2022-01-19 | Boehringer Ingelheim International GmbH | Pharmazeutische zusammensetzung mit einem glucopyranosyl-substituierten benzolderivat |
EP2698152A1 (de) | 2007-08-16 | 2014-02-19 | Boehringer Ingelheim International GmbH | Pharmazeutische Zusammensetzung mit einem glucopyranosyl-substituierten Benzolderivat |
US10022379B2 (en) | 2008-04-03 | 2018-07-17 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US10973827B2 (en) | 2008-04-03 | 2021-04-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9415016B2 (en) | 2008-04-03 | 2016-08-16 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9155705B2 (en) | 2008-04-03 | 2015-10-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9486526B2 (en) | 2008-08-06 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US10034877B2 (en) | 2008-08-06 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
EP2990037A1 (de) | 2008-08-06 | 2016-03-02 | Boehringer Ingelheim International GmbH | Diabetesbehandlung bei patienten, die nicht für die metformintherapie geeignet sind |
US8853156B2 (en) | 2008-08-06 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
EP3598974A1 (de) | 2008-08-06 | 2020-01-29 | Boehringer Ingelheim International GmbH | Diabetesbehandlung bei patienten, die nicht für die metformintherapie geeignet sind |
EP3626238A1 (de) | 2008-08-15 | 2020-03-25 | Boehringer Ingelheim International GmbH | Dpp-4-inhibitoren zur verwendung bei der behandlung von wundheilung bei diabetischen patienten |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
AU2009331471B2 (en) * | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
US9212183B2 (en) | 2008-12-23 | 2015-12-15 | Boehringer Ingelheim International Gmbh | Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
WO2010072776A1 (en) | 2008-12-23 | 2010-07-01 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
EA022310B1 (ru) * | 2008-12-23 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Солевые формы органического соединения |
WO2010079197A1 (en) | 2009-01-07 | 2010-07-15 | Boehringer Ingelheim International Gmbh | Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor |
US8846695B2 (en) | 2009-01-07 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
WO2010086411A1 (en) | 2009-01-29 | 2010-08-05 | Boehringer Ingelheim International Gmbh | Dpp-iv inhibitors for treatment of diabetes in paediatric patients |
US10406172B2 (en) | 2009-02-13 | 2019-09-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2010092124A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof |
WO2010092125A1 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
WO2010092163A2 (en) | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Antidiabetic medications |
WO2011039367A2 (en) | 2009-10-02 | 2011-04-07 | Boehringer Ingelheim International Gmbh | Therapeutic uses of pharmaceutical compositions |
EP4209210A1 (de) | 2009-10-02 | 2023-07-12 | Boehringer Ingelheim International GmbH | Pharmazeutische zusammensetzungen mit bi-1356 und metformin |
US10092571B2 (en) | 2009-11-27 | 2018-10-09 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
WO2011064352A1 (en) | 2009-11-27 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
EP3646859A1 (de) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Behandlung von genotypisierten diabetes-patienten mit dpp-iv-hemmern wie etwa linagliptin |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
US9603851B2 (en) | 2010-05-05 | 2017-03-28 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
WO2011138421A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Combination therapy |
US10004747B2 (en) | 2010-05-05 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Combination therapy |
WO2011138380A1 (en) | 2010-05-05 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations comprising pioglitazone and linagliptin |
WO2011161161A1 (en) | 2010-06-24 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
US9149478B2 (en) | 2010-06-24 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
WO2012065993A1 (en) | 2010-11-15 | 2012-05-24 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US11911387B2 (en) | 2010-11-15 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US11564886B2 (en) | 2011-03-07 | 2023-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US10596120B2 (en) | 2011-03-07 | 2020-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US20180185291A1 (en) | 2011-03-07 | 2018-07-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
WO2012120040A1 (en) | 2011-03-07 | 2012-09-13 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor |
US8962636B2 (en) | 2011-07-15 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
EP3517539A1 (de) | 2011-07-15 | 2019-07-31 | Boehringer Ingelheim International GmbH | Substituiertes dimeres chinazolinderivat, dessen herstellung und dessen verwendung in pharmazeutischen zusammensetzungen zur behandlung von diabetes typ i und ii |
US9199998B2 (en) | 2011-07-15 | 2015-12-01 | Boehringer Ingelheim Internatioal Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
WO2013010964A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
WO2013074817A1 (en) | 2011-11-16 | 2013-05-23 | Assia Chemical Industries Ltd. | Solid state forms of linagliptin |
WO2013098372A1 (en) | 2011-12-29 | 2013-07-04 | Boehringer Ingelheim International Gmbh | Subcutaneous therapeutic use of dpp-4 inhibitor |
WO2013131967A1 (en) | 2012-03-07 | 2013-09-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions comprising metformin and a dpp -4 inhibitor or a sglt-2 inhibitor |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171756A1 (en) * | 2012-03-12 | 2013-11-21 | Cadila Healthcare Limited | Amorphous form of linagliptin and process for preparation thereof |
US9879011B2 (en) | 2012-03-12 | 2018-01-30 | Cadila Healthcare Limited | Amorphous form of linagliptin and process for preparation thereof |
US10195203B2 (en) | 2012-05-14 | 2019-02-05 | Boehringr Ingelheim International GmbH | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
EP3685839A1 (de) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
US9526730B2 (en) | 2012-05-14 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US9713618B2 (en) | 2012-05-24 | 2017-07-25 | Boehringer Ingelheim International Gmbh | Method for modifying food intake and regulating food preference with a DPP-4 inhibitor |
WO2013174768A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada |
WO2013174769A1 (en) | 2012-05-25 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor |
EP2885302A4 (de) * | 2012-08-17 | 2016-03-09 | Glenmark Pharmaceuticals Ltd | Verfahren zur herstellung von dipeptidylpeptidasehemmern |
WO2014059938A1 (zh) * | 2012-10-19 | 2014-04-24 | 药源药物化学(上海)有限公司 | 一种利拉列汀重要中间体的制备方法 |
US9522915B2 (en) | 2012-10-19 | 2016-12-20 | 2Y-Chem, Ltd. | Method for preparing an important intermediate of linagliptin |
WO2014097314A1 (en) * | 2012-12-17 | 2014-06-26 | Mylan Laboratories Ltd | An improved process for the preparation of linagliptin |
EP4364796A2 (de) | 2013-03-15 | 2024-05-08 | Boehringer Ingelheim International GmbH | Verwendung von linagliptin in der kardio- und renoprotektiven antidiabetischen therapie |
US9949998B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11090323B2 (en) | 2013-04-05 | 2021-08-17 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11918596B2 (en) | 2013-04-05 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11833166B2 (en) | 2013-04-05 | 2023-12-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US10258637B2 (en) | 2013-04-05 | 2019-04-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9949997B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11666590B2 (en) | 2013-04-18 | 2023-06-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2015004599A1 (en) * | 2013-07-11 | 2015-01-15 | Wockhardt Limited | An improved process for preparing linagliptin and its key intermediates |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
WO2016207364A1 (en) | 2015-06-25 | 2016-12-29 | Boehringer Ingelheim International Gmbh | Process for the preparation of a xanthine-based compound |
EP3156048A1 (de) | 2015-10-13 | 2017-04-19 | Galenicum Health S.L. | Stabile pharmazeutische zubereitung von linagliptin in form von tabletten mit sofortiger freisetzung |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
WO2020031040A1 (en) | 2018-08-06 | 2020-02-13 | Richter Gedeon Nyrt. | Process and intermediates for the preparation of boc-linagliptin |
WO2021160608A1 (en) | 2020-02-13 | 2021-08-19 | Zakłady Farmaceutyczne POLPHARMA S.A. | Pharmaceutical composition comprising linagliptin and metformin |
WO2023156675A1 (en) | 2022-02-21 | 2023-08-24 | Krka, D.D., Novo Mesto | Process for purification of linagliptin |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3029040B1 (de) | Verfahren zur herstellung chiraler 8-(3-amino-piperidin-1-yl)-xanthine | |
DE69914921T2 (de) | Phenyl-xanthinderivate | |
DE10238470A1 (de) | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel | |
WO2015166434A1 (en) | Crystalline form of baricitinib | |
DE10327439A1 (de) | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel | |
EP2712865B1 (de) | Verbessertes Verfahren zur Herstellung von Ambrisentan | |
DE19816857A1 (de) | Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel | |
EP1444234A2 (de) | Deuterierte pyrazolopyrimidinone sowie diese verbindungen enthaltende arzneimittel | |
EP1945304A2 (de) | Imidazo-pyridin-haltige beta-agonisten, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
EP2313377B1 (de) | Verfahren zur stereoselektiven synthese bicyclischer heterocyclen | |
WO2007065567A1 (de) | Verfahren zur herstellung von haloalkyl(thio)vinimidiniumsalzen und 4- (haloalkyl(thio))-pyrazolen und deren umsetzung zu pflanzenschutzmitteln | |
AU2012205240B2 (en) | Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005804601 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 07037956AA Country of ref document: CO Ref document number: 07037956A Country of ref document: CO Ref document number: 07037956 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2586938 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3176/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580037243.1 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 182923 Country of ref document: IL Ref document number: 2007539576 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/005404 Country of ref document: MX Ref document number: 12007500962 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005300559 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 555324 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077012615 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: A200705849 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200700974 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2005300559 Country of ref document: AU Date of ref document: 20051102 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005300559 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005804601 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0517093 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 211015 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 220891 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020127034452 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020147013135 Country of ref document: KR |